FIRST AMENDMENT TO EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTExclusive Supply and Distribution Agreement • August 14th, 2006 • Cell Power Technologies Inc • Patent owners & lessors
Exclusive Supply and Distribution AgreementExclusive Supply and Distribution Agreement • July 30th, 2021 • CytoDyn Inc. • Pharmaceutical preparations • Delaware
CYTODYN INC. (“CytoDyn”), a corporation incorporated and legally existing under the laws of USA, with its principal office and place of business at 1111 Main Street, Suite 660, Vancouver, Washington 98660, hereby duly represented in accordance with its By-Laws, and
CONFIDENTIAL TREATMENT REQUESTED [***] – CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (“[***]”). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.Exclusive Supply and Distribution Agreement • April 30th, 2014 • Cryolife Inc • Surgical & medical instruments & apparatus • Georgia
This EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENT (the “Agreement”) is made and entered into effective as of March 26, 2014 (the “Effective Date”) by and between Hancock Jaffe Laboratories , Inc., a corporation organized under the laws of the state of Delaware (“HJL”), with an address at 70 Doppler, Irvine, California 92618 and CryoLife, Inc., a Florida corporation (“CL”), with an address at 1655 Roberts Blvd. NW, Kennesaw, Georgia 30144, (hereinafter sometimes individually or collectively referred to as a “Party” or the “Parties,” respectively).
EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTExclusive Supply and Distribution Agreement • July 30th, 2021 • CytoDyn Inc. • Pharmaceutical preparations
This Exclusive Supply and Distribution Agreement (“Agreement”), made and entered into this 15th day of April, 2021 (“Effective Date”), by and between:
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and...Exclusive Supply and Distribution Agreement • July 1st, 2021 • GX Acquisition Corp. • Pharmaceutical preparations
FLORHAM PARK, NJ, and NAPLES, FL, July 01, 2021— Celularity Inc. (“Celularity”), a clinical-stage biotechnology company developing innovative cell therapies and biomaterial products derived from the postpartum human placenta to treat cancer, infectious and degenerative diseases, and Arthrex, Inc., a global leader in minimally invasive orthopedic technology, today announced the companies have entered into an exclusive partnership to distribute and commercialize Celularity’s biomaterial products for orthopedic surgery and sports medicine. Under the terms of the agreement, Celularity will provide Arthrex with exclusive commercial distribution rights for orthopedic surgery and sports medicine and will continue to be responsible for product manufacturing and supply.
EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTExclusive Supply and Distribution Agreement • July 30th, 2021 • CytoDyn Inc. • Pharmaceutical preparations • New Jersey
This Exclusive Supply and Distribution Agreement (“Agreement”), made and entered into this 11th day of May, 2021 (“Effective Date”), by and between:
EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENTExclusive Supply and Distribution Agreement • September 5th, 2024
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions. EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENT BY AND AMONG 3M COMPANY, THROUGH ITS 3M DRUG DELIVERY SYSTEMS DIVISION, 3M...Exclusive Supply and Distribution Agreement • March 16th, 2005 • Sepracor Inc /De/ • Pharmaceutical preparations • Delaware
THIS AGREEMENT, effective as of November 16, 2004, ("Effective Date") is by and between 3M COMPANY, a Delaware corporation, through its 3M Drug Delivery Systems Division, and 3M Innovative Properties Company, both having offices at 3M Center, St. Paul, Minnesota 55144, (hereinafter "3M" and "3M IPC", respectively), and SEPRACOR Inc., a Delaware corporation, having its principal office at 84 Waterford Drive, Marlborough, MA 01752 (hereinafter called "SEPRACOR") (together "the Parties").
Amendment No.1 to Exclusive Supply and Distribution AgreementExclusive Supply and Distribution Agreement • July 30th, 2021 • CytoDyn Inc. • Pharmaceutical preparations
This amendment (this “Amendment”), dated as of April 19, 2021, is entered by and between CytoDyn Inc., a Delaware corporation (“CytoDyn”) having a place of business at 1111 Main Street, Vancouver, Washington 98660, and Chiral Pharma Corporation, a Philippines corporation (“CPC”) having a place of business at P. Antonio St., cor F. Legaspi St., Ugong, Pasig, Metro Manila, with respect to the following facts:
